StockStory.org on MSN9h
3 Reasons Investors Watch United Therapeutics (UTHR)United Therapeutics shares have sunk to $308.27, producing a disappointing 14% loss - worse than the S&P 500’s 1.4% drop.
Hosted on MSN1mon
United Therapeutics Stock Down Despite Q4 Earnings & Sales BeatUnited Therapeutics’ key phase III programs include Tyvaso in patients with various forms of chronic fibrosing interstitial lung disease (TETON studies) and oral ralinepag in PAH indications ...
JACKSONVILLE, Fla., October 23, 2024--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, and its subsidiary Lung Bioengineering Inc. (LBE) announced that the 500th lung ...
United Therapeutics’ UTHR fourth-quarter 2024 ... for PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD) indications. Tyvaso DPI recorded sales of $273.2 million ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback